Medarex has presented data from two of its onging Phase I/II trials of MDX-210, which reveal promising activity in late-stage breast cancer patients. All patients enrolled into the studies had failed multiple courses of other anticancer regimens.
In a US study, patients were treated with multiple doses of MDX-210 in combination with G-CSF. Of 12 patients treated with a six-week course of the drug, three showed regression or stabilization of disease and went on to a second course, two patients reported relief of bone pain, one patient showed shrinkage in a lymph node metastasis, and another patient experienced significant bone marrow metastasis clearance which removed her dependency on transfusions.
A European study tested various doses of MDX-210 in a single-dose regimen with G-CSF. This study found that around one third of patients experienced stabilization of disease over a 60-day follow-up period. Larger Phase II trials of MDX-210 in advanced breast cancer patients should begin in the very near future, according to Medarex.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze